Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2019 / Articles / Oct / Predicting All Outcomes
Manufacture Technology and Equipment Technology & Manufacturing

Predicting All Outcomes

A machine learning algorithm aims to take the “what ifs” out of chemical synthesis

By Maryam Mahdi 10/24/2019 0 min read Quick Read (pre 2022)

Share

Synthetic chemists who want to conduct novel reactions typically turn to the results of previous experiments to help ascertain the optimal conditions for enantioselectivity – and the likelihood of success. But it’s a time-consuming and error-prone process. Matthew Sigman, a chemist at the University of Utah, estimates that there can be anywhere between seven and ten variables in a typical pharmaceutical reaction. “With billions of possibilities, you cannot cover all the variable space with any type of high throughput operation,” he says. 

Tapping into the power of AI and machine learning, Sigman and Jolene Reid – another chemist at Utah – have been able to predict the outcome of chemical reactions by analyzing previously published chemical reaction data (1).

“We hope our research will allow chemists to make informed decisions about reaction conditions before beginning experimentation, effectively streamlining the drug discovery process,” says Reid. “Previously, such predictive models were generated for single reactions; however, our research shows that selectivity models can be built and generalized over a range of reactions without affecting the accuracy in prediction.”

Enantioselectivity is sensitive to any reaction component, including temperature and the type of solvent used, and so the team used multivariate linear regression, a machine learning algorithm, to dig into the impact of all reaction parameters by analyzing 367 data entries collected from 17 literature reports on the enantioselectivity of imines. Reid explains that imines are synthetically important molecules with lots of data available on their reactions types – a prerequisite for the team’s analysis. The resulting model was able to predict the outcome of 15 reactions involving one reactant that wasn’t in the original set, and the team went on to predict 13 more reactions, whose reactants and catalyst were not included in the original data.

Now, the team’s goal is to create more general models that would enable the prediction of experiments with reaction conditions that look very different to those in the original set. They also plan to use their tools to better understand the limitations of predictive models, so that chemists will know the reliability of predictions that are used to guide optimal experimental conditions.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. JP Reid and MS Sigman, “Holistic prediction of enantioselectivity in asymmetric catalysis”. Available at https://go.nature.com/2mPWjTf. Last accessed: September 30, 2019.

About the Author(s)

Maryam Mahdi

After finishing my degree, I envisioned a career in science communications. However, life took an unexpected turn and I ended up teaching abroad. Though the experience was amazing and I learned a great deal from it, I jumped at the opportunity to work for Texere. I'm excited to see where this new journey takes me!

More Articles by Maryam Mahdi

False

Advertisement

Recommended

False

Related Content

Battle of the Superbugs
Drug Discovery Technology and Equipment
Battle of the Superbugs

December 1, 2014

0 min read

Can phage endolysins revolutionize the way bacterial infections are treated – and prevent drug resistance?

All a Big Game?
Business Practice Technology and Equipment Trends & Forecasts
All a Big Game?

November 6, 2014

0 min read

“Welcome to Big Pharma, where you can make a fortune and still maintain a healthy conscience. Or can you?”

Beware the Dragonfly
Business Practice Technology and Equipment Trends & Forecasts
Beware the Dragonfly

November 6, 2014

0 min read

Mysterious cyber attackers are hitting pharma manufacturing systems

Future Proofing Track and Trace
Standards & Regulation Technology and Equipment
Future Proofing Track and Trace

November 6, 2014

0 min read

The US is finally introducing regulation on drug serialization and traceability, but gaps remain that could leave patients vulnerable.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.